Teva and Lonza Review Biosimilars Opportunity - - BioPharm International

ADVERTISEMENT

Teva and Lonza Review Biosimilars Opportunity



Teva and Lonza have announced that their joint venture will continue to develop, manufacture and market affordable, efficacious and safe biosimilars. The biosimilars arena presents significant opportunities and both companies are set on finding the best routes to realizing the benefits that safe biosimilars of certain biologic pharmaceuticals will bring to the society.

There is, however, significant regulatory uncertainty with biosimilars at present. Teva and Lonza are, therefore, taking a measured approach. Both companies have agreed to fully evaluate the prevailing regulatory and commercial circumstances before making any further long-term investment decisions on their joint venture.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

J&J Speeds Ebola Vaccine Development and Expands Production
October 24, 2014
Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Manufacturing Challenges of mAb Production: CHO or Plant Cells?
October 24, 2014
Celgene and Sutro Partner on ADC Development
October 24, 2014
GSK Accelerates Ebola Vaccine Development
October 24, 2014
Author Guidelines

Click here